Cloud-based User Platform Expanded To Support New Offerings
BANGALORE, India and GLEN BURNIE, Maryland, Jan. 14, 2013 /CNW/ - Infosys, a global leader in consulting and technology, has partnered with NovaSom, Inc., the leader in home testing for obstructive sleep apnea (OSA), to
significantly improve the efficiency of administering and analyzing
results of home tests.
Infosys has designed an innovative cloud-based user portal, Meditrack®,
on Salesforce.com to broaden the reach and efficiency of NovaSom's
diagnostic solution suite. The new portal provides physicians with a
single, easy-to-use interface that speeds up the order-to-delivery of
devices, processing of diagnostic data and management of insurance
claims.
Meditrack® provides Web interfaces with third-party applications to
access and analyze patient data immediately upon wireless receipt of
the completed home sleep test. The portal, launched earlier this year,
enables NovaSom to shorten the time from test completion to report
generation by two days. This capability helps NovaSom's sleep
specialist customers deliver faster diagnoses to patients and speed
their paths to treatment.
"Patients with OSA are at an increased risk of other chronic diseases.
The innovative solution that we developed for NovaSom is helping OSA
patients receive faster and better medical care, said Dheeshjith V.G.,
Senior Vice President and Global Head, Life Sciences at Infosys.
"Leveraging our deep medical technology domain knowledge and harnessing
the latest technical advancements has allowed us to enable NovaSom to
facilitate rapid diagnostic and therapy cycles."
The NovaSom diagnostic solution also leverages AccuSom®, the first and
only FDA-cleared wireless home sleep testing device. With more than 18
million moderate to severe cases of OSA in the United States, NovaSom's
suite of accurate, cost-effective home sleep testing solutions is
delivering new benefits to patients, health insurers, and specialty and
primary care physicians.
In 2012, NovaSom expanded its product suite, launching AccuSom Deliver™,
a customized turnkey solution allowing sleep specialists to incorporate
high-quality, at-home sleep testing into their practices on a larger
scale. AccuSom Safe Recovery™ was also launched this year, which
leverages AccuSom's wireless functionality to complete home sleep
testing prior to surgery. The new portal from Infosys has helped
NovaSom scale operations to meet the expanded solution portfolio more
effectively. Sleep specialists, surgeons, and anesthesiologists can now
develop a patient management plan that further minimizes the risk of
adverse respiratory events and other OSA-related complications during
and after surgery.
"A quicker OSA diagnosis is critical to helping sufferers get the
therapy they need sooner, and we are achieving that goal with the help
of Infosys," said Richard Hassett, MD, Chief Executive Officer,
NovaSom. "The customized MediTrack portal enables us to complete tests
quickly and accurately. NovaSom's cloud-based infrastructure allows us
to partner with providers to improve access to care, reduce cost and
address this undiagnosed epidemic."
About NovaSom
NovaSom, Inc. is the market leader in obstructive sleep apnea home
testing, with the AccuSom Home Sleep Test, the first and only
FDA-cleared wireless HST. The NovaSomhome sleep testing technology and
MediTrack portal have been shown to provide in-home, clinically
equivalent diagnosis of OSA at a significantly reduced cost as compared
to in-facility testing for uncomplicated, adult OSA. NovaSom's home
sleep tests are currently covered for more than 165 million Americans
through partnerships with major health insurers.
NovaSom also offers comprehensive service programs that are utilized by
payers, employers, primary care and sleep specialist physicians
nationwide, that enable significant cost savings for OSA management. In
an effort to combat the growing OSA epidemic, NovaSom also partners
with sleep centers, enabling sleep specialists to offer clinically
appropriate patients an alternative, convenient testing option,
expanding access to diagnosis and treatment.
NovaSom is accredited by the Joint Commission as an Ambulatory Care
Sleep Diagnostic Center & Telehealth Provider and is approved by CMS as
an Independent Diagnostic Testing Facility. For more information, visit
http://www.NovaSom.com.
About Infosys
Infosys partners with global enterprises to drive their innovation-led
growth. That's why Forbes ranked Infosys 19th among the top 100 most
innovative companies. As a leading provider of next-generation
consulting, technology, and outsourcing solutions, Infosys helps
clients in more than 30 countries realize their goals. Visit http://www.infosys.com and see how Infosys (NYSE: INFY), with its 150,000+ people, is Building
Tomorrow's Enterprise® today.
Safe Harbor
Certain statements in this release concerning our future growth
prospects are forward-looking statements, which involve a number of
risks and uncertainties that could cause actual results to differ
materially from those in such forward-looking statements. The risks and
uncertainties relating to these statements include, but are not limited
to, risks and uncertainties regarding fluctuations in earnings,
fluctuations in foreign exchange rates, our ability to manage growth,
intense competition in IT services including those factors which may
affect our cost advantage, wage increases in India, our ability to
attract and retain highly skilled professionals, time and cost overruns
on fixed-price, fixed-time frame contracts, client concentration,
restrictions on immigration, industry segment concentration, our
ability to manage our international operations, reduced demand for
technology in our key focus areas, disruptions in telecommunication
networks or system failures, our ability to successfully complete and
integrate potential acquisitions, liability for damages on our service
contracts, the success of the companies in which Infosys has made
strategic investments, withdrawal or expiration of governmental fiscal
incentives, political instability and regional conflicts, legal
restrictions on raising capital or acquiring companies outside India,
and unauthorized use of our intellectual property and general economic
conditions affecting our industry. Additional risks that could affect
our future operating results are more fully described in our United
States Securities and Exchange Commission filings including our Annual
Report on Form 20-F for the fiscal year ended March 31, 2012 and on
Form 6-K for the quarters ended December 31, 2011, June 30, 2012 and
September 30, 2012.These filings are available at http://www.sec.gov. Infosys may, from time to time, make additional written and oral
forward-looking statements, including statements contained in the
company's filings with the Securities and Exchange Commission and our
reports to shareholders. The company does not undertake to update any
forward-looking statements that may be made from time to time by or on
behalf of the company.
SOURCE: Infosys
